Advertisement

Topics

Biocept and UT Southwestern Medical Center Announce Study to Profile & Monitor NSCLC Cancer Patients with ALK Rearrangements

09:29 EDT 18 Aug 2017 | Speciality Pharma Journal

SAN DIEGO, Aug. 17, 2017 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces it has entered into a clinical study agreement with the University of Texas Southwestern Medical Center (UT Southwestern Medical Center). …

Original Article: Biocept and UT Southwestern Medical Center Announce Study to Profile & Monitor NSCLC Cancer Patients with ALK Rearrangements

NEXT ARTICLE

More From BioPortfolio on "Biocept and UT Southwestern Medical Center Announce Study to Profile & Monitor NSCLC Cancer Patients with ALK Rearrangements"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...